Exact Sciences Co. (NASDAQ:EXAS) EVP Sells $140,000.00 in Stock

Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) EVP Sarah Condella sold 2,000 shares of the company's stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the transaction, the executive vice president now owns 73,787 shares in the company, valued at approximately $5,165,090. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Sarah Condella also recently made the following trade(s):

• On Friday, March 1st, Sarah Condella sold 1,724 shares of Exact Sciences stock. The shares were sold at an average price of $59.32, for a total transaction of $102,267.68.
• On Tuesday, February 27th, Sarah Condella sold 1,880 shares of Exact Sciences stock. The shares were sold at an average price of $56.89, for a total transaction of $106,953.20.
• On Friday, February 23rd, Sarah Condella sold 1,021 shares of Exact Sciences stock. The shares were sold at an average price of $59.72, for a total transaction of $60,974.12.
• On Wednesday, February 21st, Sarah Condella sold 1,079 shares of Exact Sciences stock. The shares were sold at an average price of $61.50, for a total transaction of $66,358.50.
• On Thursday, February 15th, Sarah Condella sold 965 shares of Exact Sciences stock. The shares were sold at an average price of $61.43, for a total transaction of $59,279.95.
• On Tuesday, January 2nd, Sarah Condella sold 2,000 shares of Exact Sciences stock. The shares were sold at an average price of $73.50, for a total transaction of $147,000.00.

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded up $1.35 during midday trading on Monday, reaching $70.41. 3,173,529 shares of the stock traded hands, compared to its average volume of 2,050,319. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. The stock has a market capitalization of $12.78 billion, a PE ratio of -61.76 and a beta of 1.25. Exact Sciences Co. has a one year low of $56.05 and a one year high of $100.77. The company's 50 day moving average is $61.95 and its 200 day moving average is $65.09.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. The firm had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The company's quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.72) EPS. On average, equities research analysts anticipate that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EXAS has been the subject of several research reports. Canaccord Genuity Group reduced their price target on shares of Exact Sciences from $100.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday, February 22nd. Wolfe Research initiated coverage on shares of Exact Sciences in a research report on Wednesday, December 13th. They set an "outperform" rating and a $95.00 price target for the company. TheStreet lowered shares of Exact Sciences from a "c-" rating to a "d+" rating in a research report on Monday, February 26th. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Benchmark raised shares of Exact Sciences from a "hold" rating to a "buy" rating and set a $91.00 target price for the company in a report on Tuesday, January 2nd. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $99.31.

Institutional Trading of Exact Sciences

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Exact Sciences by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 17,559,751 shares of the medical research company's stock worth $1,299,070,000 after buying an additional 115,058 shares during the last quarter. Capital World Investors lifted its position in Exact Sciences by 7.8% in the fourth quarter. Capital World Investors now owns 7,468,145 shares of the medical research company's stock worth $552,493,000 after buying an additional 539,498 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in Exact Sciences by 12.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company's stock worth $330,711,000 after buying an additional 508,764 shares during the last quarter. Geode Capital Management LLC lifted its position in Exact Sciences by 3.7% in the first quarter. Geode Capital Management LLC now owns 2,591,057 shares of the medical research company's stock worth $175,458,000 after buying an additional 91,883 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Exact Sciences by 11.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company's stock worth $137,483,000 after buying an additional 192,372 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.